Efficacy and Safety of MEthylprednisolone Administered Intravenously for the Treatment of Patients With Active AnkyLosing spondyLitis (METALL) - a 12-week, Prospective, Open-label, Pilot Study
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- The Assessment of Spondyloarthritis International Society 40 (ASAS40) response
研究概览
简要总结
In this study, efficacy of methylprednisolone in reduction of signs and symptoms (back pain, stiffness, joint pain and swelling) of active ankylosing spondylitis (AS) will be investigated. It is expected, that a single dose of methylprednisolone 500 mg given intravenously at baseline will lead to a rapid reduction of symptoms of active AS, which can be seen already 2 weeks after drug administration.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age of ≥18 years.
- •Definite diagnosis of AS according to the modified New York criteria.
- •History of an inadequate response to ≥2 nonsteroidal antiinflammatory drugs (NSAIDs) taken for at least 2 weeks each or NSAIDs intolerance.
- •Active disease as defined by the Bath Ankylosing Spondylitis DIsease Activity Index (BASDAI) value of ≥4 at screening despite concomitant treatment with an NSAID or without NSAIDs in case of intolerance.
排除标准
- •The female subject is pregnant or lactating.
- •Patients with other chronic inflammatory articular disease or systemic autoimmune disease.
- •History of inadequate response to previous anti-tumour necrosis factor (TNF) α therapy.
- •Treatment with any other investigational drug within 4 weeks of 5 half-life of the drug (whichever is longer) prior to baseline.
- •Treatments with disease modifying anti-rheumatic drugs (DMARDs) other than methotrexate within 4 weeks prior to screening (8 weeks for leflunomide or 4 weeks with a standard cholestyramine wash-out).
- •Treatment with intravenous, intramuscular or intraarticular/periarticular steroids within 4 weeks prior to screening.
- •History of oesophageal, gastric, duodenal or intestinal ulceration, clinically relevant gastrointestinal bleeding.
- •History of or current signs of coronary heart disease, myocardial infarction, stroke or transient ischemic attack, peripheral arterial thrombotic events.
- •Congestive heart failure (NYHA III-IV)
- •Uncontrolled arterial hypertension.
- •History of diabetes mellitus.
- •History of glaucoma.
- •Major surgery within 12 weeks prior to screening.
- •Evidence of any other severe uncontrolled gastrointestinal, hepatic, renal, pulmonary, cardiovascular, nervous or endocrine disorders.
- •Any active current viral, bacterial or fungal infection, a history of recurrent clinically significant infection, infections requiring treatment with antibiotics within 4 weeks prior to baseline.
- •History of chronic infection with hepatitis B or C, history of HIV infection.
- •Primary or secondary immunodeficiency.
- •Any other conditions making the patient unsuitable in the opinion of the investigator for the participation in the current study.
研究组 & 干预措施
Methylprednisolone 500 mg
Methylprednisolone 500 mg administered intravenously at baseline
干预措施: Methylprednisolone (Drug)
结局指标
主要结局
The Assessment of Spondyloarthritis International Society 40 (ASAS40) response
时间窗: Week 2
The Assessment of Spondyloarthritis International Society 40 (ASAS40) response is defined as an improvement of ≥40% and ≥2 points in at least 3 out of four following domains (and no worsening in remaining domain): * Patient global * Pain * Function (as measured by the Bath Ankylosing Spondylitis Functional Index - BASFI) * Inflammation (mean of the Bath Ankylosing Spondylitis Disease Activity Index - BASDAI question 5 and 6)
次要结局
未报告次要终点
研究者
Denis Poddubnyy
MD
Saratov State Medical University